Cutera Announces the International Limited Commercial Release of AviClear® at IMCAS World Congress 2024
February 08 2024 - 8:00AM
Business Wire
AviClear® is now available in select practices
in the United Kingdom, Europe, and Australia
CUTERA, INC. (Nasdaq: CUTR), a leading provider of aesthetic and
dermatology solutions, announced the international limited
commercial release of AviClear, the first energy-based device
FDA-cleared for the long-term treatment of mild, moderate, and
severe acne. AviClear received an enthusiastic reception at this
year’s International Master Course on Aging Science (IMCAS)
conference in Paris, France, held February 1-3.
This press release features multimedia. View
the full release here:
https://www.businesswire.com/news/home/20240208963950/en/
AviClear® is now available in select
practices in the United Kingdom, Europe, and Australia (Photo:
Cutera)
AviClear is a 1726nm laser, which targets and suppresses the
production of sebum, thereby treating acne at its source.1-3
AviClear delivers high power (100W) selectively to the sebaceous
glands, the source of sebum production, while protecting
surrounding tissue through Cutera’s AviCool™ contact cooling
technology.3,4 In an extensive pivotal clinical trial, 92% of
patients were deemed responders to the therapy (resolution of at
least half of their acne), with a 79% median reduction in
inflammatory lesion count, at the 12-month mark following the final
treatment.1
AviClear was featured in several acne-based sessions at IMCAS,
including a presentation by dermatologist Dr. David J. Goldberg.
Dr. Goldberg presented the results of 75 patients treated in his
practice with AviClear following the FDA clearance in March 2022.
The data demonstrated similar efficacy results, in a real-world
environment, as seen in the pivotal study, and highlighted the
durability of AviClear’s treatment, with some patients reaching 18
months of follow-up.5
Following IMCAS, AviClear is now commercially available, on a
limited basis, in the U.K., Europe, and Australia. Select practices
will begin training on the technology in the coming weeks.
London-based dermatologist Dr. Anjali Mahto stated, “AviClear is
one of the most exciting innovations in the world of acne in
decades. I am thrilled to add this technology to my toolbox for the
benefit of our patients.”
As one of the first international AviClear providers, cosmetic
physician Dr. Tapan Patel said, “AviClear represents a real step
change in energy-based devices as a long-term treatment option for
the management of acne. The FDA clearance, long-term data, and
real-world results give practitioners confidence that this device
offers something novel, effective, and durable.”
Since its initial launch in North America, AviClear has been
used to treat thousands of patients. The technology has received
recognition from major beauty publications and garnered numerous
awards, including Cosmopolitan’s 2023 Acne Award as Best Pro
Treatment for Active Acne.
“It was moving to witness the excitement surrounding AviClear at
IMCAS. The amount of physician and patient interest we have
received since its initial inception has been tremendous,” said
Brent Hauser, International President of Cutera, Inc. “We are
thrilled to be able to meet the broad demand for this type of
treatment by steadily increasing availability and access
globally.”
Cutera will commence a steady rollout of AviClear across the
U.K. and EU in 2024. Interested providers are encouraged to visit
www.aviclear.com for more information.
About Cutera, Inc.
Cutera is a leading provider of aesthetic and dermatology
solutions for practitioners worldwide. For over 25 years, Cutera
strives to improve lives through medical aesthetic technologies
that are driven by science and powered through partnerships. For
more information, call 1-888-4-CUTERA or visit Cutera.com.
1 Data on file. FDA clearance study. Cutera Inc.
2 O’Neill AM, Gallo RL. Host-microbiome interactions and recent
progress into understanding the biology of acne vulgaris.
Microbiome. 2018;6:177.
3 Sakamoto FH, et al. Selective photothermolysis to target
sebaceous glands: theoretical estimation of parameters and
preliminary results using a free electron laser. Lasers Surg Med.
2012;44(2):175-183.
4 Scopelliti MG, et al. Selective photothermolysis in acne
treatment: The impact of laser power. J Cosmet Dermatol.
2023;00:1.7. Manuscript in press.
5 Data on file. David J. Goldberg, MD, JD
View source
version on businesswire.com: https://www.businesswire.com/news/home/20240208963950/en/
Media: EvolveMKD Cutera@EvolveMKD.com
Investor Relations: Greg Barker, VP, Corporate FP&A,
and Investor Relations IR@Cutera.com
Cutera (NASDAQ:CUTR)
Historical Stock Chart
From Mar 2024 to Apr 2024
Cutera (NASDAQ:CUTR)
Historical Stock Chart
From Apr 2023 to Apr 2024